Price: $0.0790
$0.04
88.095%
|
Day's High:
| $0.079
| Week Perf:
| 5.33 %
|
Day's Low: |
$ 0.02 |
30 Day Perf: |
|
Volume (M): |
3 |
52 Wk High: |
$ 0.17 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.11 |
Open: |
$0.02 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
2 |
Shares
Outstanding (Millions) |
20 |
Employees |
10 |
Revenues (TTM) (Millions $) |
1 |
Net Income (TTM) (Millions $) |
0 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Remedent Inc
We specialize in the research, development, and manufacturing of oral care
and cosmetic dentistry products. We are one of the leading manufacturers of
cosmetic dentistry products in Europe. Leveraging our knowledge of regulatory
requirements regarding dental products and management’s experience in
the needs of the professional dental community, we design, develop, manufacture
and distribute our cosmetic dentistry products, including a full line of professional
dental products that are distributed in Europe, Asia, Middle East and the United
States.
In 2006 we developed a revolutionary system for manufacturing and installing
dental veneers which we branded as GlamSmile ® veneers revolutionize the
traditional one-at-a-time method of applying porcelain dental veneers. GlamSmile
veneers are attached to the front of the patient’s teeth using a patent
pending single motion placement tray which replaces the traditional one at a
time trial and error method of applying porcelain veneers, making the application
less traumatic for the patient, much easier for the dentist and perhaps most
important, far less costly than traditional dental veneers. Currently, the GlamSmile
veneers are our primary products in the professional oral care and cosmetic
dentistry product. Our veneers are supported by a line of professional veneer
whitening and teeth sensitivity solutions. Our products are sold to professionals
by distributors and sold directly to consumers by our GlamSmile Studios.
We were originally incorporated under the laws of Arizona in September 1996
under the name Remedent USA, Inc. In October 1998, we were acquired by Resort
World Enterprises, Inc., a Nevada corporation in a share exchange, and we immediately
changed our name to Remedent USA, Inc. and later to Remedent, Inc.
In the latter part of 2008, our Board of Directors approved a strategic plan
to separate our OTC business from our professional business, allowing us to
focus on the development, marketing and distribution of our products for the
professional dental market. In December 2008, we completed a restructuring in
the form of a management-led buyout of 50% of our OTC retail business (“2008
Restructuring”). The buyout was led by Mr. Robin List, our former director
and Chief Executive Officer, with financing provided by a non-affiliated foreign
investment fund. In connection with the strategic plan, we effected our OTC
restructuring through a series of transactions involving subsidiary formations,
contributions of subsidiary(ies) interests and sales of stock interests through
subsidiary transactions. As a result of the series of transactions related to
the sale, Remedent Inc. retained 50% of Remedent OTC BV, a Dutch company (“Remedent
OTC”) with Mr. List owning the other 50%. Remedent OTC owned and held
a 75% ownership interest in Sylphar Holding BV, a Dutch holding company which
owned and held the OTC operating subsidiaries (“Sylphar Holding”),
together with Concordia Fund B.V. who owned 25% of Sylphar Holding. As a result
of Remedent, Inc.’s ownership interest in Remedent OTC, Remedent, Inc.
held an ownership interest equal to 37.5% interest in Sylphar Holding. As a
result of the sale, all of the OTC business previously directly operated by
us was operated and held by Sylphar Holding. In addition, following the restructuring
we have focused our business primarily on the marketing and distribution of
our GlamSmile Veneers.
Today, our strategic plan is to focus our vertically integrated development,
manufacturing and marketing resources on selling our GlamSmile veneers direct
to consumers by using all forms of direct response media including the internet,
print, radio, television and social network media, to expand our presence in
China and Europe. In our marketing efforts we intend to emphasize the ease,
convenience, affordability and dramatic, instant results as demonstrated by
before and after photos that are attained as a result of GlamSmile veneers.
We will also feature our “Until You Smile” satisfaction guarantee.
Using the success formula we experienced in China and Belgium using a "Smile
Consultant" to help maintain control of the sales process and close the
sale, our distribution will be through both owned and operated Glamsmile Studios
as well as affiliations with existing dental practices and partner retail centers
in Asia, Middle East and Europe.
Our current strategic marketing and distribution plan includes a combination
of owned and licensed GlamSmile centers depending upon the size and location
of the market, with us managing the marketing efforts, patient communications
and sales process. We established two geographic divisions, Asia and Europe,
each of which will promote GlamSmile veneer treatments in their respective territories.
We plan to establish three types of GlamSmile Centers depending upon market
factors and government regulation.
Owned Centers . These are centers in which the Company will own, control and/or
manage all aspects of the operation including the facilities, equipment, personnel,
marketing, insurance risk and other operating costs and will either employ or
contract with dentists to perform the necessary dental services. In China, we
will continue to principally rely on our owned and operated dental GlamSmile
clinics or centers.
Licensed Centers . In many markets we will seek to identify and recruit cosmetic
dentists that have existing practices and who endorse the GlamSmile veneer products.
In these markets, we will contract with dental practices and the Company will
recognize revenue through the sale of veneer trays plus marketing and other
service fees to be charged to the dentist for services performed by the Company.
Distributors . In markets where we lack the expertise with respect to managing
marketing and where local regulation and/or custom may make it impractical to
deploy an owned or licensed center approach we will look to appoint distributors
who will be granted exclusive rights to market and distribute our GlamSmile
products directly to consumers subject to minimum performance criteria and/or
initial territory fees. In this model the distributor will be expected to invest
in all marketing and sales conversion costs in their market. Our revenues will
be derived principally from sales of our GlamSmile veneer products to the distributor.
In order to support and facilitate our growth strategy, it is our intention
to restructure our subsidiary companies to better manage our GlamSmile related
operations. In conjunction with this restructuring, we intend to have the intellectual
property and other assets related to GlamSmile contributed to a new entity to
be formed to be called GlamSmile Worldwide. New entities would also be created
called GlamSmile Asia and GlamSmile Europe, each with licensed rights to use
and exploit the GlamSmile technology in their respective territories.
Starting in Belgium and the Netherlands, our products have been introduced
utilizing our Distributor Assisted Marketing programs. We implement our program
by first identifying an established dealer in each market with a well-developed
sales force familiar with sales of capital equipment to the professional dentist
community. Second, we develop aggressive lead generation programs and other
marketing techniques which served as a blue print for the dealers to implement.
The combination of a well-trained dealer force and dealer-assisted marketing
and lead generation programs has proven to be far more effective than utilizing
a direct sales approach, which is much slower and more costly to establish.
This process has been repeated for both the professional dentist and retail,
over-the-counter markets in each country. As a result of this approach, we have
been able to establish dealers in 28 countries encompassing, Europe, Asia, Latin
America, the Pacific Rim and the Middle East.
We previously sold our GlamSmile product in the United States and throughout
the world with the exception of certain excluded territories and certain B2C
markets pursuant to a distribution agreement. However, on March 27, 2012, the
distribution agreements with Den-Mat were terminated pursuant to a certain Termination
and Distribution Agreement with Den-Mat (“Den-Mat Distribution Agreement”).
Pursuant to the Den-Mat Distribution Agreement, we granted Den-Mat a non-exclusive,
irrevocable, perpetual, royalty free, license to use within certain territory,
which among other territories excludes China, Macau, Hong Kong, and Taiwan,
the intellectual property that was the subject of the license to Den-Mat under
the Amended and Restated Distribution, License and Manufacturing Agreement dated
June 3, 2009, as amended from time to time (“Prior Agreements”),
as such intellectual property relates the products which was the subject of
the Prior Agreements. In connection with the termination of the Prior Agreements,
under the Den-Mat Distribution Agreement, Den-Mat paid us $200,000. We currently
sell our products in Asia, Europe and the Middle East directly to consumers
using our direct to consumer model, which includes our GlamSmile Smile Design-Virtual
Studio, and GlamSmile Studios.
|
|
Customers Net Income grew by |
REMI's Customers Net Profit Margin grew to |
377.27 % |
1.54 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Co Diagnostics Inc
Co Diagnostics Inc Announces Strong Revenue Growth and Declining Inventories Salt Lake City, March 14, 2024 - Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has reported its financial results for the full year ended December 31, 2023. The company's revenue for the fourth quarter of 2023 showed a remarkable growth of 140.476% year on year, amounting to $3.37 million. However, they experienced a loss of $-0.50 per share during this period. In comparison to other companies in the Medical Equipment and Supplies sector, Co Diagnostics Inc exhibited higher revenue growth. While the overall sector saw a revenue growth of 6.78% in the fourth quarter of 2023 relative to the same period a year ago, Co Diagnostics Inc surpassed this with its substantial increase.
|
Nephros Inc
As a Wall Street journalist, it is important to analyze the financial performance of companies like Nephros Inc in order to provide valuable insights to investors. For the fiscal fourth quarter of 2023, Nephros Inc reported a loss of $0.06 per share, which was an improvement from the loss of $0.16 per share in the same period a year prior. However, compared to the previous financial reporting period, the company's loss per share increased from $0.02. Despite the mixed results in terms of earnings, Nephros Inc saw a significant increase in revenue, with a growth rate of 67.971% to $3.44 million from $2.05 million in the same period last year. The company also reported a net loss of $0.654 million for the fiscal fourth quarter of 2023, compared to a loss of $1.527 million in the same period a year ago. While Nephros Inc's stockpiles increased to $2.5 million, it is worth noting that this level remains below the previous year's level of $3.2 million. The build-up in accounts receivable is a positive sign of rising demand, with accounts receivable valued at $1.5 million, higher than in the preceding quarter. Looking at the full-year results for 2023, Nephros Inc reported revenue of $13.41 million and a net loss of $1.58 million. The company managed to decrease its loss per share to $0.15 from $0.73 in the previous fiscal year, while revenue surged by 34.39% from $9.98 million a year prior.
|
Non Invasive Monitoring Systems Inc
The Medical Equipment and Supplies sector has been closely monitoring the performance of Non Invasive Monitoring Systems Inc as it enters the second quarter of 2024. The company has reported an operating loss of $-0.04 million for the period of November to January 31, 2024, with no mention of revenue figures thus far. This lack of revenue has raised concerns among sector contributors who are looking for signs of growth and financial stability. The Chief Financial Officer of Non Invasive Monitoring Systems Inc is actively pursuing various business strategies in an effort to expand the company's product line and increase profitability. However, the company continues to struggle, reporting a net loss of $-0.054 million for the same period. This represents an increase from the net loss of $-0.048 million reported during the similar period a year ago.
|
Anika Therapeutics Inc
In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price. Financial Performance Overview: During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $43.25 million, representing a growth of 9.151% year-on-year. In comparison to its contemporaries in the Medical Equipment and Supplies sector, Anika Therapeutics Inc.'s top-line growth outpaced the industry average, highlighting its strong market position.
|
Cytosorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies, has reported its financial performance for the fiscal period between October and December 31, 2023. While the company faced some challenges during this period, it also made significant progress and achieved notable accomplishments in the medical equipment and supplies sector. Financial Performance Summary During the mentioned fiscal span, Cytosorbents Corporation experienced a widening of diminishing returns, with a decrease of $0.12 per share compared to $0.02 a year ago. However, the company managed to improve its EPS from -$0.21 per share in the previous reporting season. Revenue declined by 15.714% to $7.91 million from $9.39 million in the same reporting season a year ago. Sequentially, revenue also deteriorated by 8.04% from $8.61 million.
|
Per Share |
Current |
Earnings (TTM) |
-0.02 $ |
Revenues (TTM) |
0.06 $
|
Cash Flow (TTM) |
0.01 $ |
Cash |
0 $
|
Book Value |
0.23 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.02 $
|
Revenues (TTM) |
0.06 $ |
Cash Flow (TTM) |
0.01 $ |
Cash |
0 $
|
Book Value |
0.23 $ |
Dividend (TTM) |
0 $ |
|
|
|
|